Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Oct 25, 2022 11:07pm
158 Views
Post# 35048659

RE:RE:RE:Recent study

RE:RE:RE:Recent studyI gave a reference a few weeks ago pointing to high sortilin expression in high grade prostate cancers in comparison with low grade tumors of the same cancer. This is in the first paragraph of the discussion section. It seems to confirm that some high grade prostate cancers can be very good if TH1902 really works as described.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884004/

In addition, the level of NTSR3/sortilin in high-grade gliomas and aggressive prostate cancers was higher than those in normal and low-grade (or indolent) tumor tissues 


jfm1330 wrote: Another reference confirms that sortilin is overexpressed and involved in neuroendocrine tumors and metastasis of these tumors. Good for me to read that, hope for the future. Imagine being saved at some point in time y the company I was invested in. It would be an amazing story.

The article also confirms overexpression of sortilin in aggressive prostate cancers, which is good for us to know considering the results of phase Ia. This article also confirms what I was talking about the other day, sortilin is found in the membranes of the Golgi apparatus and the endoplasmic reticulum, which could explain why through endosome internalization TH1902 can bypass efflux pump. Also, Golgi and ER are involved with tubulin, the protein that docetaxel is interacting with.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884004/


Wino115 wrote: Great find. Ours boys research is mentioned twice - footnotes 38 and 88.  Getting some recognition for the PDC and sort1 target!


 




<< Previous
Bullboard Posts
Next >>